Tamsulosin and the Risk of Serious Adverse Events

Exclusion criteria

• ✕. Data cleaning exclusions (e.g., individuals with missing or invalid age or administrative database number, OHIP ineligible on index date, death on or before the index date, non-Ontario residents). The investigators anticipate that very few records will be excluded due to data cleaning.
• ✕. The investigators will exclude patients receiving tamsulosin doses other than 0.4mg/day or 0.8mg/day.
• ✕. To ensure that patients are new tamsulosin users, the investigators will exclude those with any evidence of tamsulosin use in the 180 days before the index date.
• ✕. Patients with more than one study drug prescription on the index date will be excluded, as this complicates the ability to ascertain the prescribed dose accurately.
• ✕. The investigators will exclude patients with a prescription of Alpha1 blocker (alfuzosin, doxazosin, prazosin, silodosin, terazosin), 5 Alpha Reductase inhibitor (dutasteride, finasteride, dutasteride \& tamsulosin), and non-oral study drugs in the previous 180 days, including the index date.
• ✕. Individuals with end-stage renal disease, chronic dialysis, or a kidney transplant prior to the index date.
• ✕. Evidence with hospital discharge or emergency department visit in the two days prior to or on the index date to ensure a new outpatient prescription.
• ✕. Patients with no outpatient serum creatinine measurement 0- 365 days before the index date will be excluded.